208 related articles for article (PubMed ID: 32673439)
1. Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.
Oldham M; Conrey A; Pittman C; Fisher C; Hargrett S; West K; Jackson M; Martin S; Hsieh MM; Jeffries N; Kaplarevic M; Johnson D; Olkhanud P; Fitzhugh CD
J Clin Pharmacol; 2021 Jan; 61(1):41-51. PubMed ID: 32673439
[TBL] [Abstract][Full Text] [Related]
2. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
3. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
5. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
Dong M; Mizuno T; Vinks AA
Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
[TBL] [Abstract][Full Text] [Related]
6. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.
Fitzhugh CD; Hsieh MM; Allen D; Coles WA; Seamon C; Ring M; Zhao X; Minniti CP; Rodgers GP; Schechter AN; Tisdale JF; Taylor JG
PLoS One; 2015; 10(11):e0141706. PubMed ID: 26576059
[TBL] [Abstract][Full Text] [Related]
8. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
9. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
11. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
F1000Res; 2018; 7():. PubMed ID: 30228870
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
13. The role of hydroxyurea in the management of sickle cell disease.
Davies SC; Gilmore A
Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
[TBL] [Abstract][Full Text] [Related]
14. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
15. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
16. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Brandow AM; Panepinto JA
Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease.
Ogu UO; Mukhopadhyay A; Patel K; Nelson MN; Strahan KS; Wu L; Smeltzer MP; Ataga KI
Eur J Haematol; 2024 Mar; 112(3):466-474. PubMed ID: 38019026
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]